Roche Holding AG (RO.SW) SIX after hours CHF356.60 26 Jan 2026: earnings due 29 Jan may reset outlook
RO.SW stock closed after hours at CHF 356.60 on SIX on 26 Jan 2026 as investors position ahead of Roche Holding AG’s earnings report due 29 Jan 2026. The market is watching revenue growth, EPS of 11.73, and the company’s diagnostics momentum. Volume was 13,200 versus a 50-day average of 26,118, suggesting cautious trading. This earnings spotlight will test Roche’s premium multiple and guide near-term price action for the Switzerland-listed healthcare leader.
RO.SW stock: After-hours move and earnings timing
Roche Holding AG (RO.SW) is trading in after hours on SIX at CHF 356.60 after a regular session close of CHF 356.00. The stock traded between CHF 352.00 and CHF 357.00 during the day with 13,200 shares changing hands. The key catalyst is the scheduled earnings announcement on 29 Jan 2026, which markets expect to clarify guidance and margin drivers.
Earnings will be the dominant near-term driver for RO.SW stock. Investors should watch revenue, core EPS, and any comments on U.S. pricing and Genentech manufacturing spend.
RO.SW stock: Q4 earnings preview and key metrics
Roche reports EPS of 11.73 trailing twelve months and currently trades at a PE of 30.38. Recent financials show free cash flow per share of 15.68 and dividend per share of 9.70, giving a dividend yield near 2.79%. Revenue per share stands at 58.01, which supports defensive sector status.
Analysts will parse margins and R&D intensity. Roche’s diagnostics growth and Genentech investments are likely to shape guidance and any one-off items reported in Q4.
RO.SW stock: Meyka AI rates and forecast model
Meyka AI rates RO.SW with a score out of 100: 69.14 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus.
Meyka AI’s forecast model projects a monthly price of CHF 368.98, implying about 3.47% upside from the current CHF 356.60. These model-based projections are not guarantees and should be used with other research. For full company context see Roche’s site and market quotes Bloomberg and a detailed profile at StockAnalysis.
RO.SW stock: Valuation, technicals and price targets
Valuation: RO.SW shows a TTM PE near 30.38, price-to-book 9.74, and price-to-sales 5.95, reflecting a premium to peers. Enterprise value over EBITDA sits around 24.33, indicating stretched multiples versus sector averages.
Technicals: RSI is 70.92 (overbought) and ADX at 39.65 signals a strong trend. Short-term momentum is positive but overbought conditions raise the odds of a pullback. Suggested targets: conservative CHF 300.00, base fair value CHF 340.00, bullish CHF 420.00, depending on earnings clarity and pipeline updates.
RO.SW stock: Risks, opportunities and sector context
Opportunities include continued diagnostics growth, approvals such as Lunsumio VELO, and Genentech manufacturing scale-up. Recent expansions in North Carolina underline capacity gains and revenue optionality.
Risks include Swiss pricing headwinds from U.S. drug pricing deals, pipeline setbacks, and elevated valuation metrics. In the broader Switzerland healthcare sector, RO.SW stock trades on a premium versus peers but retains defensive traits and high R&D intensity.
RO.SW stock: Trading action and analyst watch
Trading setup favors event-driven moves into the earnings release. Average volume is 26,118; today’s lower volume implies selective positioning. Traders may use tightened stops given the overbought momentum.
Watch for post-earnings guidance revisions and any comment on pricing in Switzerland. For active tracking use our Meyka AI-powered market analysis tools and the Roche company site for filings.
Final Thoughts
Key takeaways for RO.SW stock: Roche is priced at CHF 356.60 on SIX as of 26 Jan 2026, with an EPS of 11.73 and a PE of 30.38 that reflect premium expectations. The upcoming 29 Jan 2026 earnings release is the immediate catalyst and could shift valuation toward a conservative CHF 300.00 or a bullish CHF 420.00 scenario. Meyka AI’s forecast model projects a monthly target of CHF 368.98, implying 3.47% upside from the current price; forecasts are model-based projections and not guarantees. Investors should weigh diagnostics momentum and Genentech investment against Swiss pricing headwinds and high multiples before adjusting positions.
FAQs
When will Roche report earnings and why does it matter for RO.SW stock?
Roche reports earnings on 29 Jan 2026. The report matters for RO.SW stock because it will update revenue, EPS, and guidance. Investors watch diagnostics growth and Genentech investments to judge near-term valuation and price direction.
What are the main valuation metrics to watch for RO.SW stock?
Key metrics include PE 30.38, EPS 11.73, price-to-book 9.74, and EV/EBITDA around 24.33. These show a premium valuation that earnings and guidance must justify for RO.SW stock to advance.
How does Meyka AI view RO.SW stock right now?
Meyka AI rates RO.SW 69.14 out of 100 (Grade B, HOLD). The grade balances sector comparison, growth metrics, and forecasts. It is informational and not investment advice for RO.SW stock.
What short-term price action should traders expect for RO.SW stock?
Expect event-driven volatility around the earnings release. RSI 70.92 signals overbought conditions, so traders should manage risk. Volume below the 50-day average suggests selective flows into RO.SW stock.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
